Neuronetics shares surge 46.58% after-hours after reporting 86% Q4 revenue growth and $34.1M cash balance.

Neuronetics surged 46.58% in after-hours trading following the release of preliminary unaudited Q4 2025 financial results showing $41.8 million in revenue, up 86% year-over-year on an as-reported basis and 23% on an adjusted pro forma basis. The company reported $18.3 million in NeuroStar revenue, a 9% pro forma increase, and $23.5 million in clinic revenue, a 37% pro forma rise, alongside $0.9 million in positive operating cash flow. Full-year 2025 revenue reached $149.2 million, reflecting 99% year-over-year growth. The results highlighted strong commercial execution across both segments, robust cash flow generation, and a $34.1 million cash balance, bolstering investor confidence in the company’s operational and financial trajectory.